SBC Medical Group Holdings (SBC) AI Stock Analysis

40 Followers

SBC Medical Group Holdings

(NASDAQ:SBC)

Select Model

Rating:80Outperform

Price Target:$6.50▲(24.05% Upside)

Action:reiterated

Date:09/22/26

The score is driven primarily by strong financial performance (high margins, healthy ROE, low leverage) and a constructive earnings outlook with improving growth/profit metrics and identified AI-driven upside. The main offsets are stretched technical momentum (overbought signals) and ongoing execution/consistency risks (historical volatility, concentration in aesthetic services, and timing of AI/international benefits).

Positive Factors

High margins and profitabilityStrong and consistently high margins indicate effective cost control and attractive economics in SBC’s services model. Healthy profitability can support reinvestment in clinics, technology, and expansion while providing resilience if revenue growth becomes uneven over the next several quarters.

Negative Factors

Revenue and cash-flow volatilityThe business has demonstrated uneven demand and cash conversion despite strong trailing results. A prior revenue decline and substantial historical cash-flow swings make recent acceleration harder to underwrite as a stable trend, potentially complicating investment and expansion planning.

SBC Medical Group Holdings (SBC) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $538.92M
Dividend Yield: ―
Average Volume (3M): 206.43K
Price to Earnings (P/E): 11.1
Beta (1Y): 0.48
Revenue Growth: -6.92%
EPS Growth: 46.87%
Country: US
Employees: 863
Sector: Industrials
Sector Strength: 63
Industry: Consulting Services

SBC Medical Group Holdings Business Overview & Revenue Model

Company Description

SBC Medical Group Holdings Incorporated provides comprehensive operational support to aesthetic and cosmetic clinics across a global footprint, including Japan, Vietnam, the United States, and other international markets. The company delivers a diver...

SBC Medical Group Holdings Earnings Call Summary

Earnings Call Date:Aug 13, 2026(Q2-2026)|% Change Since:63.75%|Next Earnings Date:Nov 13, 2026

Earnings Call SentimentPositive

The call conveyed multiple strong operational and financial improvements: double-digit revenue growth, a 32% rise in adjusted EBITDA and margin expansion to 41%, network expansion (+34 locations YoY), rising customer metrics, clear multi-brand and AI-driven strategies, and actionable international initiatives. Challenges flagged were manageable in the near term (one-time SG&A items, currency headwind) and longer-term execution risks around AI rollouts, international scaling and diversification away from aesthetic services. On balance, the positives (strong growth, profitability gains, AI and product/brand initiatives, ample capital for disciplined M&A) materially outweigh the noted challenges.

Positive Updates

Strong Top- and Bottom-Line Growth

Q2 revenue of $49M, up 13% year-over-year; Adjusted EBITDA $20M, up 32% YoY, yielding an adjusted EBITDA margin of 41% — profit growth outpaced revenue growth.

Negative Updates

SG&A Higher Than Expected

SG&A rose slightly versus expectations; management attributed much of the increase to one-time costs related to a secondary offering, though near-term expense pressure was noted.

Company Guidance

The company guided to a reacceleration of growth supported by network expansion, AI-driven service upsell and international rollouts, backing that with many concrete metrics: as of June 2026 SBC had 287 locations (up 34 YoY) and 6.92M trailing‑12‑month visits (up 10%); year‑to‑date clinic revenue rose 11%, same‑clinic revenue +6% and average spend per visit +9%; Q2 revenue was $49M (+13% YoY) with adjusted EBITDA $20M (+32%) and a 41% adjusted EBITDA margin. Management highlighted H1 transaction‑value growth of ~19% for key brands (Gorilla Clinic H1 transaction value $62M, +19%), a transaction mix ~84% aesthetic /16% non‑aesthetic, a target to raise average fee per clinic by roughly $15M/year from AI and call‑center initiatives ($11M call center, $4M Gorilla/Rize) (partial impact in H2, full contribution next fiscal year), OrangeTwist at 24 U.S. locations with >40% recurring revenue, a shareholder base ~4.7x larger YoY (July 2026), ~26 years of data fueling AI, net cash ~45% of market cap, and a long‑term goal of 1,000 clinics by 2035 (longevity center planned 2027).

SBC Medical Group Holdings Financial Statement Overview

Summary

Strong profitability and returns (TTM gross margin ~71%, net margin ~28%, EBIT margin ~42%; ROE ~19%) alongside low leverage (debt-to-equity ~0.08) support a high score. The main offset is historical volatility in revenue and cash conversion (notably weaker 2025 revenue vs. 2024 and uneven multi-year cash flow), which raises sustainability questions despite very strong TTM results.

Income Statement

82Very Positive

Balance Sheet

86Very Positive

Cash Flow

79Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	175.17M	173.61M	205.42M	193.54M	174.16M
Gross Profit	124.84M	127.28M	156.05M	137.30M	114.83M
EBITDA	77.62M	84.91M	77.28M	85.87M	29.64M
Net Income	49.03M	50.99M	46.61M	39.37M	6.32M
Balance Sheet
Total Assets	406.66M	380.45M	266.08M	258.81M	225.48M
Cash, Cash Equivalents and Short-Term Investments	184.62M	164.09M	125.04M	103.02M	53.64M
Total Debt	48.23M	51.64M	12.21M	22.87M	16.13M
Total Liabilities	126.74M	117.14M	71.06M	115.00M	117.63M
Stockholders Equity	263.84M	248.28M	195.11M	142.16M	105.25M
Cash Flow
Free Cash Flow	60.70M	22.30M	17.17M	39.44M	-24.99M
Operating Cash Flow	62.82M	24.67M	20.58M	50.64M	-47.37K
Investing Cash Flow	-36.33M	-20.97M	-10.10M	1.82M	-32.65M
Financing Cash Flow	27.59M	38.29M	22.97M	6.14M	-7.98M

SBC Medical Group Holdings Technical Analysis

Technical Analysis SentimentPositive

Last Price5.24

Price Trends

50DMA5.02Positive

100DMA4.16Positive

200DMA3.94Positive

Market Momentum

MACD0.05Positive

RSI52.27Neutral

STOCH40.05Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SBC, the sentiment is Positive. The current price of 5.24 is below the 20-day moving average (MA) of 5.32, above the 50-day MA of 5.02, and above the 200-day MA of 3.94, indicating a neutral trend. The MACD of 0.05 indicates Positive momentum. The RSI at 52.27 is Neutral, neither overbought nor oversold. The STOCH value of 40.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SBC.

SBC Medical Group Holdings Risk Analysis

SBC Medical Group Holdings disclosed 79 risk factors in its most recent earnings report. SBC Medical Group Holdings reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

1 New Risk

1.Because we are not currently in compliance with certain Nasdaq corporate governance requirements, Nasdaq may delist our securities from trading on its exchange, which could limit investors' ability to make transactions in our securities and subject us to additional trading restrictions.Q2, 2026

SBC Medical Group Holdings Peers Comparison

Overall Rating

UnderperformOutperform

Sector (63)

Financial Indicators

SBC against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SBC	80Outperform	$544.06M	11.15	19.31%	―	-6.92%	46.87%
ICFI	73Outperform	$1.49B	15.50	9.20%	0.68%	-5.16%	-0.04%
HURN	70Outperform	$2.63B	24.55	26.67%	―	12.30%	11.07%
CRAI	66Neutral	$1.25B	24.83	26.28%	1.14%	12.67%	-4.24%
FCN	64Neutral	$5.38B	24.87	15.43%	―	7.77%	1.87%
Sector *	63Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
RGP	45Neutral	$96.12M	-2.01	-25.92%	10.22%	-19.60%	76.21%

* Industrials Sector Average

Performance Comparison

SBC and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SBC	Sbc Medical Group Holdings Incorporated	5.24	1.88	55.95%
CRAI	CRA International	200.14	21.18	11.84%
FCN	FTI Consulting	197.21	32.25	19.55%
HURN	Huron Consulting Group	168.16	6.39	3.95%
ICFI	Icf International	82.77	4.11	5.23%
RGP	Resources Connection Inc.	2.74	-1.62	-37.11%

SBC Medical Group Holdings Corporate Events

Business Operations and StrategyFinancial Disclosures

SBC Medical Group Posts Strong Q2 2026 Profit Rebound

Positive

Aug 13, 2026

On August 13, 2026, SBC Medical Group Holdings reported second-quarter 2026 results showing a sharp rebound in profitability following its 2025 restructuring, with revenue up 13% year-on-year to $49 million and net income attributable to the company...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 22, 2026

SBC Medical Group Holdings AI Stock Analysis